Items Tagged ‘RBC’

August 31st, 2016

Revlimid® Reduces Need for Blood Transfusions in Some Myelodysplastic Syndromes


The agent Revlimid (lenalidomide) reduces the need for blood transfusions among patients with lower-risk, non-del (5q) myelodysplastic syndromes who are dependent upon red blood cell transfusions, but are not eligible for erythropoiesis-stimulating agents. These results were recently published in the Journal of Clinical Oncology. Myelodysplastic syndromes (MDS) refer to a group of diseases in which […]

View full entry

Tags: clinical trial, General Myelodysplastic Syndrome, lenalidomide, MDS, Myelodysplastic Syndrome, News, RBC, revlimid